Neuroprotection by the Endogenous Cannabinoid Anandamide and Arvanil Against in Vivo Excitotoxicity in the Rat: Role of Vanilloid Receptors and Lipoxygenases

Overview

Journal J Neurosci

Specialty Neurology

Date 2003 May 24

PMID 12764100

Citations 51

Authors

W B Veldhuis

M van der Stelt

M W Wadman

G van Zadelhoff

M Maccarrone

F Fezza

G A Veldink

J F G Vliegenthart

P R Bar

K Nicolay

V Di Marzo

Affiliations

Soon will be listed here.

Abstract

Type 1 vanilloid receptors (VR1) have been identified recently in the brain, in which they serve as yet primarily undetermined purposes. The endocannabinoid anandamide (AEA) and some of its oxidative metabolites are ligands for VR1, and AEA has been shown to afford protection against ouabain-induced in vivo excitotoxicity, in a manner that is only in part dependent on the type 1 cannabinoid (CB1) receptor. In the present study, we assessed whether VR1 is involved in neuroprotection by AEA and by arvanil, a hydrolysis-stable AEA analog that is a ligand for both VR1 and CB1. Furthermore, we assessed the putative involvement of lipoxygenase metabolites of AEA in conveying neuroprotection. Using HPLC and gas chromatography/mass spectroscopy, we demonstrated that rat brain and blood cells converted AEA into 12-hydroxy-N-arachidoylethanolamine (12-HAEA) and 15-hydroxy-N-arachidonoylethanolamine (15-HAEA) and that this conversion was blocked by addition of the lipoxygenase inhibitor nordihydroguaiaretic acid. Using magnetic resonance imaging we show the following: (1) pretreatment with the reduced 12-lipoxygenase metabolite of AEA, 12-HAEA, attenuated cytotoxic edema formation in a CB1 receptor-independent manner in the acute phase after intracranial injection of the Na+/K+-ATPase inhibitor ouabain; (2) the reduced 15-lipoxygenase metabolite, 15-HAEA, enhanced the neuroprotective effect of AEA in the acute phase; (3) modulation of VR1, as tested using arvanil, the VR1 agonist capsaicin, and the antagonist capsazepine, leads to neuroprotective effects in this model, and arvanil is a potent neuroprotectant, acting at both CB1 and VR1; and (4) the in vivo neuroprotective effects of AEA are mediated by CB1 but not by lipoxygenase metabolites or VR1.

Citing Articles

The TRPV1-PKM2-SREBP1 axis maintains microglial lipid homeostasis in Alzheimer's disease.

Sha X, Lin J, Wu K, Lu J, Yu Z Cell Death Dis. 2025; 16(1):14.

PMID: 39809738 PMC: 11732990. DOI: 10.1038/s41419-024-07328-8.

Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years.

Maccarrone M, Di Marzo V, Gertsch J, Grether U, Howlett A, Hua T Pharmacol Rev. 2023; 75(5):885-958.

PMID: 37164640 PMC: 10441647. DOI: 10.1124/pharmrev.122.000600.

Reward enhances resilience to chronic social defeat stress in mice: Neural ECs and mGluR5 mechanism neuroprotection in VTA and DRN.

Shi P, Hu L, Ren H, Dai Q Front Psychiatry. 2023; 14:1084367.

PMID: 36873216 PMC: 9978385. DOI: 10.3389/fpsyt.2023.1084367.

TRPV1 regulates ApoE4-disrupted intracellular lipid homeostasis and decreases synaptic phagocytosis by microglia.

Wang C, Lu J, Sha X, Qiu Y, Chen H, Yu Z Exp Mol Med. 2023; 55(2):347-363.

PMID: 36720919 PMC: 9981624. DOI: 10.1038/s12276-023-00935-z.

Anti-Microbial Activity of Phytocannabinoids and Endocannabinoids in the Light of Their Physiological and Pathophysiological Roles.

Sionov R, Steinberg D Biomedicines. 2022; 10(3).

PMID: 35327432 PMC: 8945038. DOI: 10.3390/biomedicines10030631.

References

Nagayama T, Sinor A, Simon R, Chen J, Graham S, Jin K . Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci. 1999; 19(8):2987-95. PMC: 6782289. View

Jung Y, Cho T, Moon C, Lee B, Lee S, Shin H . Systemically administered capsazepine prevents the capsaicin-induced functional desensitization and loss of substance P-like immunoreactivity (SP-LI) in guinea-pig bronchi. Life Sci. 1999; 64(14):PL173-7. DOI: 10.1016/s0024-3205(99)00057-0. View

Szallasi A, Blumberg P . Vanilloid (Capsaicin) receptors and mechanisms. Pharmacol Rev. 1999; 51(2):159-212. View

Zygmunt P, Petersson J, Andersson D, Chuang H, Sorgard M, Di Marzo V . Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature. 1999; 400(6743):452-7. DOI: 10.1038/22761. View

Melck D, Bisogno T, De Petrocellis L, Chuang H, Julius D, Bifulco M . Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors. Biochem Biophys Res Commun. 1999; 262(1):275-84. DOI: 10.1006/bbrc.1999.1105. View

Sinor A, Irvin S, Greenberg D . Endocannabinoids protect cerebral cortical neurons from in vitro ischemia in rats. Neurosci Lett. 2000; 278(3):157-60. DOI: 10.1016/s0304-3940(99)00922-2. View

Smart D, Gunthorpe M, Jerman J, Nasir S, Gray J, Muir A . The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br J Pharmacol. 2000; 129(2):227-30. PMC: 1571834. DOI: 10.1038/sj.bjp.0703050. View

Mezey E, Toth Z, Cortright D, Arzubi M, Krause J, Elde R . Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proc Natl Acad Sci U S A. 2000; 97(7):3655-60. PMC: 16295. DOI: 10.1073/pnas.97.7.3655. View

Gonsiorek W, Lunn C, Fan X, Narula S, Lundell D, Hipkin R . Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. Mol Pharmacol. 2000; 57(5):1045-50. View

10.

Hwang S, Cho H, Kwak J, Lee S, Kang C, Jung J . Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances. Proc Natl Acad Sci U S A. 2000; 97(11):6155-60. PMC: 18574. DOI: 10.1073/pnas.97.11.6155. View

11.

Di Marzo V, Breivogel C, Bisogno T, Melck D, Patrick G, Tao Q . Neurobehavioral activity in mice of N-vanillyl-arachidonyl-amide. Eur J Pharmacol. 2000; 406(3):363-74. DOI: 10.1016/s0014-2999(00)00687-7. View

12.

Liu L, Oortgiesen M, Li L, Simon S . Capsaicin inhibits activation of voltage-gated sodium currents in capsaicin-sensitive trigeminal ganglion neurons. J Neurophysiol. 2001; 85(2):745-58. DOI: 10.1152/jn.2001.85.2.745. View

13.

Di Marzo V, Bisogno T, De Petrocellis L, Brandi I, Jefferson R, Winckler R . Highly selective CB(1) cannabinoid receptor ligands and novel CB(1)/VR(1) vanilloid receptor "hybrid" ligands. Biochem Biophys Res Commun. 2001; 281(2):444-51. DOI: 10.1006/bbrc.2001.4354. View

14.

de Graaf R, Braun K, Nicolay K . Single-shot diffusion trace (1)H NMR spectroscopy. Magn Reson Med. 2001; 45(5):741-8. DOI: 10.1002/mrm.1101. View

15.

Di Marzo V, Lastres-Becker I, Bisogno T, De Petrocellis L, Milone A, Davis J . Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues. Eur J Pharmacol. 2001; 420(2-3):123-31. DOI: 10.1016/s0014-2999(01)01012-3. View

16.

Shishido Y, Furushiro M, Hashimoto S, Yokokura T . Effect of nordihydroguaiaretic acid on behavioral impairment and neuronal cell death after forebrain ischemia. Pharmacol Biochem Behav. 2001; 69(3-4):469-74. DOI: 10.1016/s0091-3057(01)00572-x. View

17.

van der Stelt M, Veldhuis W, Bar P, Veldink G, Vliegenthart J, Nicolay K . Neuroprotection by Delta9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity. J Neurosci. 2001; 21(17):6475-9. PMC: 6763099. View

18.

Craib S, Ellington H, Pertwee R, Ross R . A possible role of lipoxygenase in the activation of vanilloid receptors by anandamide in the guinea-pig bronchus. Br J Pharmacol. 2001; 134(1):30-7. PMC: 1572923. DOI: 10.1038/sj.bjp.0704223. View

19.

Panikashvili D, Simeonidou C, Hanus L, Breuer A, Mechoulam R, Shohami E . An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature. 2001; 413(6855):527-31. DOI: 10.1038/35097089. View

20.

van der Stelt M, Veldhuis W, van Haaften G, Fezza F, Bisogno T, Bar P . Exogenous anandamide protects rat brain against acute neuronal injury in vivo. J Neurosci. 2001; 21(22):8765-71. PMC: 6762287. View